Review article: The chemoprevention of colorectal carcinoma

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 4, 2004, Pages 31-35

  Gasche, C ^a,b  

^a Div of Gastroenterol and Hepatol   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CARCINOMA; ENTERITIS; GENE MUTATION; HUMAN; MICROSATELLITE INSTABILITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; CHEMOPREVENTION; CHROMOSOMAL INSTABILITY; COLITIS; COLORECTAL NEOPLASMS; HUMANS; MESALAMINE; MICROSATELLITE REPEATS; PRECANCEROUS CONDITIONS;

EID: 4844224142     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis [see comments]. Gastroenterology 1992; 103: 1444-51.
2. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-33.
3. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer. IBD-associated and sporadic cancer compared. Trends Mol Med 2002; 8: 10-6.
4. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-7.
5. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991; 51: 3075-9.
6. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-61.
7. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 1997; 94: 2545-50.
8. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998; 95: 8698-702.
9. Suzuki H, Harpaz N, Tarmin L, et al. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res 1994; 54: 4841-4.
10. Brentnall TA, Crispin DA, Bronner MP, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 1996; 56: 1237-40.
11. Brentnall TA, Rubin CE, Crispin DA, et al. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 1995; 109: 151-5.
12. Noffsinger AE, Belli JM, Fogt F, Fischer J, Goldman H, Fenoglio-Preiser CM, A germline hMSH2 alteration is unrelated to colonic microsatellite instability in patients with ulcerative colitis. Hum Pathol 1999; 30: 8-12.
13. Fleisher AS, Esteller M, Harpaz N, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 2000; 60: 4864-8.
14. Gasche C, Chang CL, Rhees J, Goel A, Boland CR. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res 2001; 61: 7444-8.
15. Chang CL, Marra G, Chauhan DP, et al. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 2002; 283: C148-54.
16. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107: 369-78.
17. Tarmin L, Yin J, Harpaz N, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995; 55: 2035-8.
18. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-6.
19. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-7.
20. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-23.
21. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-53.
22. Simmonds NJ, Millar AD, Blake DR, Rampton DS. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment Pharmacol Ther 1999; 13: 363-72.
23. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003; 24: 443-51.
24. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 1999; 13: 1397-402.
25. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-90.
26. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.
27. Gasche C, Chang CL, Natarajan L, et al. Identification of frame-shift intermediate mutant cells. Proc Natl Acad Sci 2003; 100: 1914-9.
28. Gasche C, Goel A, Boland CR. 5-Aminosalicylic acid (5-ASA) but not acetylsalicylic acid (aspirin) reduces the spontaneous mutation rate at a (CA) 13 microsatellite (MS). Gastroenterology 2001; 120: 651.